Search Results - "Garcia Garre, E"

A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge by Vicente Conesa, M.A., Zafra Poves, M., Carmona-Bayonas, A., Ballester Navarro, I., de la Morena Barrio, P., Ivars Rubio, A., Montenegro Luis, S., García Garre, E., Vicente, V., Ayala de la Peña, F.

“…Hospitalization of cancer patients is associated with poor overall survival, but prognostic misclassification may lead to suboptimal therapeutic decisions and…”
Get full text

2068 POSTER Incidence of amenorrhea after chemotherapy and paper of hormone therapy in the ovarian function in hormone sensitive breast cancer by Garcia Garre, E, Roselló, S.R, Jorda, E, Perez-Fidalgo, J.A, Martin, P, Bermejo, B, Magro, A, Chirivella, I, Lluch, A

Get full text

2052 POSTER Incidence of chemotherapy induced amenorrhea and the role of hormone therapy on ovarian function in hormone sensitive breast cancer by Garcia Garre, E, Rosello-Keranën, S, Jorda, E, Perez-Fidalgo, A, Martin, P, Bermejo, B, Chirivella, I, Magro, A, Insa, A, Lluch, A

Get full text

291P Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study by Martinez-Garcia, J., Boix, A. Puertes, Henarejos, P. Sanchez, Lucas, M.D. Jimenez, Saura, A. Sanchez, Luengo, M., Vicente, R. Carrillo, Ortiz, M.J. Martinez, Balsalobre, J., Barrio, P.D.L.M. de la Morena, Garre, E. Garcia, Garcia, E., Marin, G., Torralba, E. Garcia, Ayala de la Pena, F., Collado, D., Lopez, A., Quiros, T., Sánchez, D.A., Romero, J.L.A.

Get full text

915PPROGNOSTIC VALUE OF MULTIDISCIPLINAR GYNAECOLOGICAL COMMITTE IN OVARIAN CANCER PATIENTS by García-Martinez, E., Garcia-Garre, E., Garcia-Garcia, T., Vicente, V., Peña, F. Ayala de La

“…Abstract Aim: An appropriate surgical staging and optimal cytoreduction (no residual disease) is the best treatment in ovarian cancer patients (OCP). Probably…”
Get full text

Prognostic Value of Multidisciplinar Gynaecological Committe in Ovarian Cancer Patients by García-Martinez, E., Garcia-Garre, E., Garcia-Garcia, T., Vicente, V., Peña, F. Ayala de La

Get full text

Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer by Ayala de la Peña, F., Yufera Soler, J.C., Ivars, M.A., Fernandez Sanchez, A., Navarro Manzano, E., De la Morena Barrio, P., Garcia-Garre, E., Garcia-Martinez, E., Marin Zafra, G., Salguero Aguilar, R., Garcia, T.

Get full text

A Prognostic Model of Survival After First Hospital Discharge of Cancer Patients by Conesa, M.A. Vicente, Fernanadez, A., Zafra, M., De Barrio, P.La Morena, Ballester, I., Garcia-Garre, E., Urrgeo, E., Carmona-Bayonas, A., Peña, F. Ayala de La

Get full text

1405PA PROGNOSTIC MODEL OF SURVIVAL AFTER FIRST HOSPITAL DISCHARGE OF CANCER PATIENTS by Conesa, M.A. Vicente, Fernanadez, A., Zafra, M., Barrio, P. De La Morena, Ballester, I., Garcia-Garre, E., Urrgeo, E., Carmona-Bayonas, A., Peña, F. Ayala de La

“…Abstract Aim: Unplanned hospitalization of cancer patients has been associated to low survival. Although prognostic tools exist for palliative patients, no…”
Get full text

Switching to aromatase inhibitor (AI) after tamoxifen in premenopausal patients with chemotherapy-induced amenorrhea (CIA) after early breast cancer treatment by Perez-Fidalgo, J. A., Miranda, M. J., Bermejo, B., Pons, V., Rosello, S., Garcia-Garre, E., Guzman, C., Lluch, A.

“…Abstract only…”
Get full text

Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy by Chirivella, I., Bermejo, B., Insa, A., Perez-Fidalgo, A., Magro, A., Rosello, S., Garcia-Garre, E., Martin, P., Bosch, A., Lluch, A.

“…Abstract only 668 Background: The relationship between chemotherapy (CT) dose intensity and patient (pt) outcome in the management of early stage breast cancer…”
Get full text

Abstract P5-15-09: Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer by Ayala de la Peña, F, Ivars Rubio, A, de la Morena Barrio, P, Fernández Sánchez, A, Luengo Gil, G, García Martínez, E, García Garre, E, Marín Zafra, G, Vicente, V

“…Background: Sequencing of single-agent chemotherapy (CT) is the current standard of treatment for endocrine-resistant metastatic breast cancer (MBC). However,…”
Get full text

Abstract P5-01-08: Changes induced by neoadjuvant chemotherapy (NCT) in breast cancer tumor infiltrating lymphocytes (TIL) subpopulations are associated with chemo-sensitivity and prognosis by García-Martínez, E, Luengo-Gil, G, Chaves, A, Gonzalez-Billalabeitia, E, García, García T, Vicente Conesa, MA, García Garre, E, de la Morena, P, Vicente, V, Ayala de la Peña, F

“…Background: Recent data support the modulation of immune response in breast cancer microenvironment by neoadjuvant chemotherapy. This immune modulation might…”
Get full text

Abstract P3-06-15: Baseline CD4/CD8 tumor infiltrating lymphocytes (TIL) ratio predicts pathologic response to neoadjuvant chemotherapy (NC) in breast cancer by García-Martínez, E, Luengo, Gil G, Chaves, Benito A, García, García T, Vicente, Conesa AM, Zafra, Poves M, García, Garre E, Vicente, García V, Ayala, de la Peña F

“…Background: Tumor microenvironment immune response has been correlated with chemotherapy efficacy. The aim of this study was to determine whether baseline and…”
Get full text

Prognostic value of decrease on blood lymphocytes in breast cancer patients undergoing primary chemotherapy by Vicente, A., García-Martínez, E., Gonzalez-Billalabeitia, E., Zafra, M., Castilla-Llorente, C., García-García, T., Macías, J., García-Garre, E., Vicente, V., Ayala de la Peña, F.

“…Abstract only e11537 Background: There is evidence about chemotherapy creating a better tumor control by inmune system. Neoadjuvant treatment is an excellent…”
Get full text